US2290503075 - Common Stock
CYRX stock results show that CryoPort missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips CryoPort (NASDAQ:CYRX) just reported results for the first quarter of 2024.Cryo...
/PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) (Cryoport), a global leader in supply chain solutions for the life sciences, today announced financial results...
/PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX), a global leader in supply chain solutions for cell & gene therapies, today announced that the Company will...
/PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport"), a global leader in supply chain solutions for cell & gene therapies, today announced financial...
/PRNewswire/ -- Cryoport Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a leading global provider of innovative products and services to the fast-growing...
/PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a leading global provider of innovative products and services to the fast-growing...
/PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a leading global provider of innovative products and services to the life...
/PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a leading global provider of innovative products and services to the fast-growing...
/PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a leading global provider of innovative products and services to the fast-growing...
/PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a leading global provider of innovative products and services to the fast-growing...
Cryoport partners with Cell and Gene Therapy Catapult to build a global supply chain logistics center in the UK, expanding its presence in the region. Read more here.
/PRNewswire/ -- Be The Match BioTherapies®, an organization offering solutions for companies developing and commercializing cell and gene therapies, and...